{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T10:17:54Z","timestamp":1760782674628},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[1994,1,1]],"date-time":"1994-01-01T00:00:00Z","timestamp":757382400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother. Pharmacol."],"published-print":{"date-parts":[[1994]]},"DOI":"10.1007\/bf00686513","type":"journal-article","created":{"date-parts":[[2004,11,29]],"date-time":"2004-11-29T16:34:17Z","timestamp":1101746057000},"page":"527-529","source":"Crossref","is-referenced-by-count":18,"title":["Chronic oral etoposide in advanced breast cancer"],"prefix":"10.1007","volume":"33","author":[{"given":"H.","family":"Palombo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Estap\ufffd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Vi\ufffdolas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. J.","family":"Grau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. M.","family":"Ma\ufffd\ufffd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Daniels","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Mellado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"CR1","first-page":"633","volume":"60","author":"DL Ahmann","year":"1976","unstructured":"Ahmann DL, Bisel HF, Eagan RT, et al (1976) Phase II evaluation of VP16-213 (NSC-141540) and Cytembena (NSC-104801) in patients with advanced breast cancer. Cancer Treat Rep 60: 633?635","journal-title":"Cancer Treat Rep"},{"key":"CR2","first-page":"473","volume":"62","author":"F Cavalli","year":"1978","unstructured":"Cavalli F, Sonntag RW, Jungi F, et al (1978) VP-16-213 monotherapy for remission induction of small cell lung cancer: a randomized trial using three dosage schedules. Cancer Treat Rep 62:473","journal-title":"Cancer Treat Rep"},{"key":"CR3","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1200\/JCO.1987.5.1.55","volume":"5","author":"GM Glark","year":"1987","unstructured":"Glark GM, Sledge GW Jr, Osborne CK, McGuire WL (1987) Survival from first recurrence: relative importance of prognostic factors in 1,015 breast cancer patients. J Clin Oncol 5:55","journal-title":"J Clin Oncol"},{"key":"CR4","first-page":"137","volume-title":"Cancer treatment","author":"CM Haskell","year":"1985","unstructured":"Haskell CM, et al (1985) Breast cancer. In: Haskell CM (ed) Cancer treatment. W. B. Saunders, Philadelphia, pp 137?180"},{"key":"CR5","first-page":"1197","volume-title":"Cancer, principles and practice of oncology","author":"IC Henderson","year":"1989","unstructured":"Henderson IC, Harris JR, Kinne DW, Hellman S (1989) Cancer of the breast. In: De Vita VT Jr, Hellman S, Rosenberg SA (eds) Cancer, principles and practice of oncology. J. B. Lippincott, Philadelphia, p 1197"},{"key":"CR6","first-page":"715","volume":"81","author":"P Dombernbwsky","year":"1973","unstructured":"Dombernbwsky P, Nissen NI (1973) Schedule dependency of the antileukemic activity of the podophyllotoxin derivative VP16-213 (NSC-141540) in 11210 leukemia. Acta Pathol Microbiol Scand [A] 81:715","journal-title":"Acta Pathol Microbiol Scand [A]"},{"key":"CR7","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/0959-8049(92)90126-M","volume":"28A","author":"J Estap\u00e9","year":"1992","unstructured":"Estap\u00e9 J, Palombo H, Sanchez-Lloret J, et al (1992) Chronic oral etoposide in non-small cell lung carcinoma. Eur J Cancer 28A:835","journal-title":"Eur J Cancer"},{"key":"CR8","first-page":"142","volume":"14","author":"G Fraschini","year":"1989","unstructured":"Fraschini G, Esparza L, Holmes F, et al (1989) High-dose etoposide (HD-E) in metastatic breast cancer (abstract). Breast Cancer Res Treat 14:142","journal-title":"Breast Cancer Res Treat"},{"issue":"Suppl","key":"CR9","first-page":"303","volume":"67","author":"FA Greco","year":"1989","unstructured":"Greco FA, Johnson DH, Hainsworth JD, et al (1989) Chronic oral etoposide. Cancer 67 [Suppl]:303","journal-title":"Cancer"},{"key":"CR10","first-page":"395","volume":"3","author":"JD Hainsworth","year":"1990","unstructured":"Hainsworth JD, Greco A, Johnson D, et al (1990) Chronic daily administration of oral etoposide: a phase I trial. J Clin Oncol 3:395","journal-title":"J Clin Oncol"},{"key":"CR11","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1200\/JCO.1990.8.10.1613","volume":"8","author":"DH Johnson","year":"1990","unstructured":"Johnson DH, Greco FA, Strupp J, et al (1990) Prolonged administration of oral etoposide in patients with relapsed or refractory small-cell lung cancer: a phase II trial. J Clin Oncol 8:1613","journal-title":"J Clin Oncol"},{"key":"CR12","doi-asserted-by":"crossref","first-page":"13560","DOI":"10.1016\/S0021-9258(18)90729-5","volume":"259","author":"LF Liu","year":"1984","unstructured":"Liu LF, Rowe TG, Yang L, et al (1984) Cleavage of DNA by mammalian DNA topoisomerase II. J Biol Chem 259:13560","journal-title":"J Biol Chem"},{"key":"CR13","first-page":"145","volume":"8","author":"JC Miller","year":"1989","unstructured":"Miller JC, Loehrer FJ, Williams SD, et al (1989) Phase II study of daily oral VP-16 in refractory germ cell tumours (abstract). Proc Am Soc Clin Oncol 8:145","journal-title":"Proc Am Soc Clin Oncol"},{"key":"CR14","first-page":"5857","volume":"44","author":"W Ross","year":"1984","unstructured":"Ross W, Rowe T, Glisson B, Yalowich J, Liu L (1984) Role of topoisomerase II in mediating epipodophyllotoxin induced DNA cleavage. Cancer Res 44:5857","journal-title":"Cancer Res"},{"key":"CR15","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/BF00254555","volume":"7","author":"FC Schell","year":"1982","unstructured":"Schell FC, Yap HY, Hortobagyi GN, et al (1982) Phase II study of VP-16-213 (etoposide) in refractory metastatic breast carcinoma. Cancer Chemother Pharmacol 7:223","journal-title":"Cancer Chemother Pharmacol"},{"issue":"Suppl","key":"CR16","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1002\/1097-0142(19910101)67:1+<266::AID-CNCR2820671310>3.0.CO;2-A","volume":"67","author":"GW Sledge Jr","year":"1991","unstructured":"Sledge GW Jr (1991) Etoposide in the management of metastatic breast cancer. Cancer 67 [Suppl]:266","journal-title":"Cancer"},{"key":"CR17","first-page":"175","volume":"5","author":"ML Slevin","year":"1986","unstructured":"Slevin ML, Clark PI, Osborne RJ, et al (1986) A randomized trial to evaluate the effect of schedule on the activity of etoposide in small cell lung cancer. Proc Am Soc Clin Oncol 5:175","journal-title":"Proc Am Soc Clin Oncol"},{"key":"CR18","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1021\/bi00356a060","volume":"25","author":"DM Sullivan","year":"1986","unstructured":"Sullivan DM, Glisson BS, Hodges PK, et al (1986) Proliferation dependence of topoisomerase II mediated drug action. Biochemistry 25:2248","journal-title":"Biochemistry"},{"key":"CR19","first-page":"443","volume":"65","author":"CB Vaughn","year":"1981","unstructured":"Vaughn CB, Panettiere F, Thigpen T, et al. (1981) Phase II evaluation of VP-16-213 in patients with advanced breast cancer: a Southwest Oncology Group study. Cancer Treat Rep 65:443","journal-title":"Cancer Treat Rep"},{"key":"CR20","volume-title":"Handbook for reporting results of cancer treatment","author":"World Health Organization","year":"1979","unstructured":"World Health Organization (1979) Handbook for reporting results of cancer treatment. World Health Organization, Geneva"},{"key":"CR21","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6","volume":"47","author":"AB Miller","year":"1981","unstructured":"Miller AB, Hoogstraten B, Staquet M, et al (1981) Reporting results of cancer treatment. Cancer 47:207?214","journal-title":"Cancer"},{"key":"CR22","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/0021-9681(61)90060-1","volume":"13","author":"EA Gehan","year":"1961","unstructured":"Gehan EA (1961) The determination of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent. J Chronic Dis 13:4","journal-title":"J Chronic Dis"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00686513.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF00686513\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00686513","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,30]],"date-time":"2021-06-30T01:29:48Z","timestamp":1625016588000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF00686513"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1994]]},"references-count":22,"journal-issue":{"issue":"6","published-print":{"date-parts":[[1994]]}},"alternative-id":["BF00686513"],"URL":"https:\/\/doi.org\/10.1007\/bf00686513","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[1994]]}}}